WHO chief scientist disappointed by CureVac trial

18th June 202118th June 20215691 Min Read

Reading Time: < 1 minute

The World Health Organization’s chief scientist said on Friday that results from the CureVac COVID-19 vaccine’s initial trial were disappointing.

German biotech firm CureVac’ vaccine proved only 47% effective in an initial trial read-out.

“It was disappointing to see the results from CureVac,” the WHO’s Soumya Swaminathan told a news conference.

Photo: A view of a logo of biopharmaceutical company CureVac at the main building in Tuebingen, Germany. EPA-EFE/RONALD WITTEK

Highly mutated COVID variant found in new countries but pandemic in ‘a different phase’

Cde25th August 2023

A highly mutated COVID variant called BA.2.86 has now been detected in Switzerland and South Africa in addition to Israel, Denmark, the U.S. and the U.K., according to a leading W...
US CDC tracks new lineage of virus that causes COVID

Cde18th August 2023

U.S. Centers for Disease Control and Prevention said on Thursday that it was tracking a new, highly mutated lineage of the virus that causes COVID-19. The lineage is named BA.2.86...
New Covid vaccines are on the way as ‘Eris’ variant rises in US

Cde14th August 2023

A new COVID vaccine is due out next month, but health experts and analysts say it is likely to be coolly received even as hospitalizations from "Eris", a variant of the Omicron fo...